Phase I/II

Type: Keyphrase

Name: Phase I/II

First reported 13 hours ago - Updated 13 hours ago - 1 reports

BioMarin Pharmaceutical Inc. Presents at UBS Global Healthcare Conference, May-21-2013 09:00 AM

Matthew Harrison - UBS Investment Bank, Research DivisionGood morning, everybody. Thanks for joining us. I'm Matthew Harrison, one of the Biotech analyst here at UBS. Next up, we have BioMarin and I'm pleased to have the CFO, Dan Spiegelman presenting. ... [Published Seeking Alpha - 13 hours ago]

Entities: Patient, BioMarin Pharmaceutical Inc, Phase III, FDA Food & Drug Administration

First reported 23 hours ago - Updated 23 hours ago - 1 reports

R-Tech begins enrolling patients in Phase I/II severe dry eye study

R-Tech Ueno has begun enrolling patients with severe dry eye in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in US. ... [Published PBR - News - 23 hours ago]

Entities: Phase I/II, Patient, R-Tech Ueno Ltd

First reported May 20 2013 - Updated May 20 2013 - 1 reports

A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013

By :In January, I wrote an article on regenerative medicine companies that could make headway in 2013. I would like to refocus on the subject and review some of my favorite candidates in the young, but quickly growing industry of regenerative medicine. ... [Published Seeking Alpha - May 20 2013]

Entities: Regenerative Medicine, Stem Cell, Per-Se Technologies Inc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Novozymes Biopharma Helps Innovative Dry Eye Therapy Move into Clinical Trials

A novel ophthalmic solution has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States. ... [Published Technology Networks - May 20 2013]

Entities: Novozymes AS, Clinical trials, Phase I/II, Ophthalmic

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Novozymes AS

Novozymes Biopharma’s Recombinant Human Albumin Helps Dry Eye Therapy Enter Clinical Trials

A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States. Novozymes Biopharma, part of Novozymes ... [Published Pharma-Mag - May 20 2013]

Entities: Novozymes AS, Albumin, Recombinant

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Advanced Micro Devices Inc

Xcovery Vision reports encouraging data from Phase I/II AMD trial

Xcovery Vision, a biopharmaceutical company, has reported preliminary data from the Phase I/II clinical trial of the company's dual VEGFR/PDGFR inhibitor, X-82, for the treatment of neovascular wet age-related macular degeneration, or AMD. Chris Liang, ... [Published Individual.com - May 20 2013]

Entities: Advanced Micro Devices Inc, Phase I/II, Sutent, Wet Age-related Macular Degeneration

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Daratumumab Granted Breakthrough Therapy Designation for Double-Refractory Multiple Myeloma

The Food and Drug Administration has granted breakthrough therapy designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory ... [Published Oncology Times - May 18 2013]

Entities: Multiple Myeloma, Drugs, American Society of Hematology, Phase I/II, cytotoxic

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Cell Medica Announces Treatment of First Pediatric Patient in Early Stage Clinical Trial of Cytovir ADV

(NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Cell Medica announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of CytovirTM ADV for ... [Published NewsRX - May 17 2013]

Entities: Clinical trials, Patient, bone marrow transplantation, Great Ormond Street Hospital, Adenovirus

First reported May 15 2013 - Updated May 16 2013 - 5 reports

Genmab A/S (GEN.CO) Release: Daratumumab Data to be Presented at American Society of Clinical Oncology Annual Meeting

Staying up-to-date has never been simpler. Sign up for the today! Copenhagen, Denmark; May 16, 2013 â Genmab A/S (OMX: GEN) announced today that the latest data from the ongoing Phase I/II study of daratumumab in relapsed/refractory multiple myeloma will ... [Published BioSpace - May 16 2013]

Entities: Genmab AS, American Society of Clinical Oncology, Chicago May, Multiple Myeloma

First reported May 16 2013 - Updated May 16 2013 - 1 reports

La Jolla Pharmaceutical completes Phase I chronic kidney disease trial

La Jolla Pharmaceutical Company, a developer of therapeutics targeting galectin proteins, has announced the completion of Phase I trial with the treatment of the last patient in the Phase I, or Part A, portion of the Phase I/II clinical trial of GCS-100 ... [Published Individual.com - May 16 2013]

Entities: La Jolla Pharmaceutical Company, Phase I, Patient, Kidney, Clinical trials

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Bionor Pharma Reports Strengthening and Consolidation of Organization

) Bionor Pharma ASA (OSE:BIONOR) today announced financial results for first quarter 2013, $ and provided highlights of key operational developments during first quarter 2013, current status and outlook.Webcast The Q1 report will be presented by webcast ... [Published Reuters - May 15 2013]

Entities: Bionor Pharma ASA, Teleconference, Phase I/II, Nutraceuticals, HIV/AIDS

First reported Apr 29 2013 - Updated Apr 30 2013 - 5 reports

BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020

Interim results are expected by the end of 2 ... [Published Technology Networks - Apr 30 2013]

Entities: BioLineRx Ltd, Phase I/II, Clinical trials

Quotes

Market Report, "Hepacyl Therapeutics, SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile" , published

Market Report, "Hepacyl Therapeutics, SL - Pharmaceuticals & Healthcare - Deals and Alliances Pro ... [Published Live-PR.com - 20 hours ago]

Anand Sambasivan, Chief Executive of Darwin Strategic said: "With Immupharma's Lupuzor fast tracked by the FDA for pivotal Phase III trials, the Company is approaching an important inflection point.The EFF bolsters ImmuPharma's financing security as it prepares for this next stage on Lupuzor while continuing to develop its drug pipeline."

?50M Financing Facility - Darwin Strategic [Published Best Invest - 23 hours ago]

"The data shows that 50mg of X-82 once daily achieves exposures well above the concentration required to inhibit new blood vessel formation which suggests that the dose should be well tolerated and could be efficacious in treating wet AMD patients" said Dr Liang. Dr Liang is one of the developers of Sutent and scientific founder of Xcovery Vision

Xcovery Vision reports encouraging data from Phase I/II AMD trial [Published Individual.com - May 20 2013]

"As the present fire stations are in Phase I II, III and in Ucotech-II, we have planned to construct stations in other regions as well, so that less time is wasted in reaching the spot. Three stations will be built in the industrial belt, while one will be built in Sector 39, which is a residential area. Each station is estimated to cover a population of around 2.5 lakh" he said

4 fire stations to be set up in Noida, Greater Noida [Published New Delhi Pioneer - May 19 2013]

More Content

sort by: Date \| Relevance
Amicus Therapeutics' CEO Presents at 2013 UBS G... [Published Seeking Alpha - 6 hours ago]
Seattle Genetics Inc. Presents at UBS Global He... [Published Seeking Alpha - 10 hours ago]
IPO Preview: Portola Pharmaceuticals [Published Seeking Alpha - 11 hours ago]
Amgen, Inc. Management Presents at UBS Global H... [Published Seeking Alpha - 11 hours ago]
BioMarin Pharmaceutical Inc. Presents at UBS Gl... [Published Seeking Alpha - 13 hours ago]
Market Report, "Hepacyl Therapeutics, SL - Phar... [Published Live-PR.com - 20 hours ago]
New Market Report Now Available: Adocia (ADOC) ... [Published Live-PR.com - 20 hours ago]
R-Tech begins enrolling patients in Phase I/II ... [Published PBR - News - 23 hours ago]
?50M Financing Facility - Darwin Strategic [Published Best Invest - 23 hours ago]
IPO Preview: Alcobra Pharmaceuticals [Published Seeking Alpha - 23 hours ago]
Chasing the cure for Parkinson’s disease [Published PMLive - May 21 2013]
Astex Pharmaceuticals, Inc. Presents at UBS Glo... [Published Seeking Alpha - May 20 2013]
Medivation, Inc. Presents at UBS Global Healthc... [Published Seeking Alpha - May 20 2013]
Advaxis, Inc. (ADXS) Continues To Impress [Published Seeking Alpha - May 20 2013]
Ariad Pharmaceuticals Inc. Presents at UBS Glob... [Published Seeking Alpha - May 20 2013]
A Focus On Stem-Cell Therapy And Regenerative M... [Published Seeking Alpha - May 20 2013]
Novozymes Biopharma Helps Innovative Dry Eye Th... [Published Technology Networks - May 20 2013]
Novozymes Biopharma’s Recombinant Human Albumin... [Published Pharma-Mag - May 20 2013]
Xcovery Vision reports encouraging data from Ph... [Published Individual.com - May 20 2013]
BioMarin Pharmaceutical Inc. Reports Inducement... [Published Noodls - May 20 2013]
Recombinant human albumin from Novozymes Biopha... [Published News-Medical.Net - May 20 2013]
R-Tech Ueno: Start of the Patient Enrollment of... [Published EON Business - May 20 2013]
R-Tech Ueno: Start of the Patient Enrollment of... [Published Business Wire Communications News - May 20 2013]
R-Tech Ueno: Start of the Patient Enrollment of... [Published Business Wire Science: Science News - May 20 2013]
R-Tech Ueno: Start of the Patient Enrollment of... [Published Business Wire Health News - May 20 2013]
4 fire stations to be set up in Noida, Greater ... [Published New Delhi Pioneer - May 19 2013]
Market Report, "Hidd Power Company (BSC) - Stra... [Published PR inside - May 19 2013]
Effective vaccination against borreliosis possible [Published Health Canal - May 19 2013]
Adocia (ADOC) - Pharmaceuticals & Healthcare - ... [Published TransWorldNews - May 18 2013]
A Journey To Add Biotech To The Portfolio [Published Seeking Alpha - May 18 2013]